Recent Mergers and Acquisitions


Mergers and acquisitions (M&A) serve as an integral tool for BD in advancing its strategy of improving patient outcomes, reducing the cost of care, expanding access and enhancing the operations of our customers around the world. In recent years BD has completed dozens of tuck-in acquisitions including TVA Medical, Medafor, and Kiestra Lab Automation, and we continue to seek out attractive opportunities which align with the strategies of BD’s businesses and regions.

BD has developed leading capabilities in transactional structuring, execution, due diligence and integration. BD's Corporate Development team partners with our businesses, functions and regions to evaluate potential opportunities. All M&A opportunities should be directed to our Corporate Development team based out of our global headquarters in Franklin Lakes, New Jersey, USA through the website submission form below.

M&A Criteria

BD seeks inorganic opportunities that advance our long-term strategy through increasing patient access, driving better outcomes, managing system cost pressures, and improving health care safety. Directional criteria is provided below:

  • Differentiated technologies
  • Attractive underlying market growth
  • Global reach and application
  • Digital and connected devices / solutions
  • Medication management
  • Infectious disease diagnostics
  • Vascular access management
  • Chronic disease management (diabetes, PAD, ESRD)
  • Surgical procedures and urological disorders
  • Immunology research and testing

Submit your interest or inquiry

Submit an acquisition opportunity
To submit an acquisition proposals on a NON-CONFIDENTIAL basis, please complete the form below. Please note, BD will be under no obligation to treat any information provided in this manner as confidential regardless of any legend or statement contained therein or set forth with respect thereto.

To submit a licensing or new product proposal: Click here